204 related articles for article (PubMed ID: 9671311)
1. Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development.
Amendt C; Schirmacher P; Weber H; Blessing M
Oncogene; 1998 Jul; 17(1):25-34. PubMed ID: 9671311
[TBL] [Abstract][Full Text] [Related]
2. Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis.
Go C; Li P; Wang XJ
Cancer Res; 1999 Jun; 59(12):2861-8. PubMed ID: 10383147
[TBL] [Abstract][Full Text] [Related]
3. Expression of a dominant-negative mutant TGF-beta type II receptor in transgenic mice reveals essential roles for TGF-beta in regulation of growth and differentiation in the exocrine pancreas.
Böttinger EP; Jakubczak JL; Roberts IS; Mumy M; Hemmati P; Bagnall K; Merlino G; Wakefield LM
EMBO J; 1997 May; 16(10):2621-33. PubMed ID: 9184209
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-beta signaling helps specify tumor type in DMBA and hormone-induced mammary cancers.
Crowley MR; Frost A; Chen DT; Baffi MO; Nicola T; Serra R
Differentiation; 2006 Feb; 74(1):40-52. PubMed ID: 16466399
[TBL] [Abstract][Full Text] [Related]
5. Dominant-negative interference of the transforming growth factor beta type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice.
Gorska AE; Joseph H; Derynck R; Moses HL; Serra R
Cell Growth Differ; 1998 Mar; 9(3):229-38. PubMed ID: 9543389
[TBL] [Abstract][Full Text] [Related]
6. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene.
Böttinger EP; Jakubczak JL; Haines DC; Bagnall K; Wakefield LM
Cancer Res; 1997 Dec; 57(24):5564-70. PubMed ID: 9407968
[TBL] [Abstract][Full Text] [Related]
7. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.
Tang B; de Castro K; Barnes HE; Parks WT; Stewart L; Böttinger EP; Danielpour D; Wakefield LM
Cancer Res; 1999 Oct; 59(19):4834-42. PubMed ID: 10519393
[TBL] [Abstract][Full Text] [Related]
8. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
Tobin SW; Douville K; Benbow U; Brinckerhoff CE; Memoli VA; Arrick BA
Oncogene; 2002 Jan; 21(1):108-18. PubMed ID: 11791181
[TBL] [Abstract][Full Text] [Related]
9. Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II.
Song K; Cornelius SC; Danielpour D
Cancer Res; 2003 Aug; 63(15):4358-67. PubMed ID: 12907605
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
Parekh TV; Gama P; Wen X; Demopoulos R; Munger JS; Carcangiu ML; Reiss M; Gold LI
Cancer Res; 2002 May; 62(10):2778-90. PubMed ID: 12019154
[TBL] [Abstract][Full Text] [Related]
11. TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest.
Paterson IC; Davies M; Stone A; Huntley S; Smith E; Pring M; Eveson JW; Robinson CM; Parkinson EK; Prime SS
Oncogene; 2002 Feb; 21(10):1616-24. PubMed ID: 11896591
[TBL] [Abstract][Full Text] [Related]
12. Aberrant cell cycle progression contributes to the early-stage accelerated carcinogenesis in transgenic epidermis expressing the dominant negative TGFbetaRII.
Go C; He W; Zhong L; Li P; Huang J; Brinkley BR; Wang XJ
Oncogene; 2000 Jul; 19(32):3623-31. PubMed ID: 10951568
[TBL] [Abstract][Full Text] [Related]
13. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
[TBL] [Abstract][Full Text] [Related]
14. TGF beta regulation of cell proliferation.
Moses HL; Arteaga CL; Alexandrow MG; Dagnino L; Kawabata M; Pierce DF; Serra R
Princess Takamatsu Symp; 1994; 24():250-63. PubMed ID: 8983080
[TBL] [Abstract][Full Text] [Related]
15. Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis.
Weeks BH; He W; Olson KL; Wang XJ
Cancer Res; 2001 Oct; 61(20):7435-43. PubMed ID: 11606377
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta receptor expression on human skin fibroblasts: dimeric complex formation of type I and type II receptors and identification of glycosyl phosphatidylinositol-anchored transforming growth factor-beta binding proteins.
Tam BY; Philip A
J Cell Physiol; 1998 Sep; 176(3):553-64. PubMed ID: 9699508
[TBL] [Abstract][Full Text] [Related]
17. Influence of beta1 integrins on epidermal squamous cell carcinoma formation in a transgenic mouse model: alpha3beta1, but not alpha2beta1, suppresses malignant conversion.
Owens DM; Watt FM
Cancer Res; 2001 Jul; 61(13):5248-54. PubMed ID: 11431366
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma.
Paterson IC; Matthews JB; Huntley S; Robinson CM; Fahey M; Parkinson EK; Prime SS
J Pathol; 2001 Apr; 193(4):458-67. PubMed ID: 11276004
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.
Bierie B; Stover DG; Abel TW; Chytil A; Gorska AE; Aakre M; Forrester E; Yang L; Wagner KU; Moses HL
Cancer Res; 2008 Mar; 68(6):1809-19. PubMed ID: 18339861
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
Yang F; Strand DW; Rowley DR
Oncogene; 2008 Jan; 27(4):450-9. PubMed ID: 17637743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
